CSL rout extends into sixth session after CEO departure, weak earnings

Csl

12/02/2026 01:26

** Shares of CSL Ltd CSL.AX fall 7.8% to A$150.660, extending losses into their sixth consecutive session

** Stock is down 15% for the week, with most of the losses coming since Wednesday, after CEO Paul McKenzie announced retirement

** If the trend holds, CSL would post its worst week since late October

** CSL on Wednesday also reported an 81% drop in its first-half profit, hurt by weaker plasma and vaccine sales and one-off charges

** CSL stock, once the priciest in Australia, is down 43% since August, when it first announced the spinoff of its influenza vaccine division, Seqirus, and flagged a broader restructuring

** CSL stock's relative strength index (RSI) dipped below 30 on Wednesday for the first time since early November — a threshold market participants consider indicative of being oversold

** CSL stock down 11.6% this year, including the day's move

(Reporting by Sameer Manekar in Bengaluru)

((Sameer.Manekar@thomsonreuters.com))